Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma

S. Chiara, M. Bruzzone, L. Merlini, P. Bruzzi, R. Rosso, P. Franzone, M. Orsatti, V. Vitale, G. Foglia, F. Odicino, N. Ragni, S. Rugiati, P. Conte

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Between January 1989 and December 1991, 64 patients with advanced cervical carcinoma FIGO stage IIb-III were randomized to receive radiotherapy (RT) alone or the sequential combination of chemotherapy (CT) and RT. RT consisted of external RT (40 Gy fractionated over 4 weeks) + brachytherapy (40 Gy to point A) + an additional boost to the parameters (15-20 Gy) in arm RT; CT consisted of cisplatin 60 mg/m2 i.v. day 1 q 15 days administered for 2 cycles before the start of RT and for 4 cycles after the end of radiation treatment in CT + RT arm. Among the 58 evaluable patients objective response rate was as follows: in RT arm, CR in 40.7% of patients, PR in 40.7%, and SD in 18.6%; in CT + RT arm, CR in 42% of patients, PR in 35.5%, and SD in 22.5%. The median duration of response was 12 months (range: 3-38 + months). At a median follow-up of 36 months survival (S) and progression-free survival (PFS) were 83% and 72.4% in RT arm, 72% and 59.3% in CT + RT arm, respectively. No significant difference was observed between the 2 treatment arms, neither in terms of objective response nor in terms of S and PFS. Both treatments were generally well tolerated. In our experience the addition of chemotherapy to standard radiotherapy does not enhance morbidity and does not interfere with the correct delivery of the planned treatment. However, results of this combined modality regimen remain unsatisfactory, since no improvement in pelvic control and survival of patients with advanced cervical carcinoma was observed.

Original languageEnglish
Pages (from-to)294-297
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number4
Publication statusPublished - 1994

Fingerprint

Radiotherapy
Carcinoma
Drug Therapy
Disease-Free Survival
Survival
Brachytherapy
Therapeutics
Combination Drug Therapy
Cisplatin
Radiation
Morbidity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. / Chiara, S.; Bruzzone, M.; Merlini, L.; Bruzzi, P.; Rosso, R.; Franzone, P.; Orsatti, M.; Vitale, V.; Foglia, G.; Odicino, F.; Ragni, N.; Rugiati, S.; Conte, P.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 17, No. 4, 1994, p. 294-297.

Research output: Contribution to journalArticle

Chiara, S, Bruzzone, M, Merlini, L, Bruzzi, P, Rosso, R, Franzone, P, Orsatti, M, Vitale, V, Foglia, G, Odicino, F, Ragni, N, Rugiati, S & Conte, P 1994, 'Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 17, no. 4, pp. 294-297.
Chiara, S. ; Bruzzone, M. ; Merlini, L. ; Bruzzi, P. ; Rosso, R. ; Franzone, P. ; Orsatti, M. ; Vitale, V. ; Foglia, G. ; Odicino, F. ; Ragni, N. ; Rugiati, S. ; Conte, P. / Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1994 ; Vol. 17, No. 4. pp. 294-297.
@article{eacd29de7a044336b88c670c2748e087,
title = "Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma",
abstract = "Between January 1989 and December 1991, 64 patients with advanced cervical carcinoma FIGO stage IIb-III were randomized to receive radiotherapy (RT) alone or the sequential combination of chemotherapy (CT) and RT. RT consisted of external RT (40 Gy fractionated over 4 weeks) + brachytherapy (40 Gy to point A) + an additional boost to the parameters (15-20 Gy) in arm RT; CT consisted of cisplatin 60 mg/m2 i.v. day 1 q 15 days administered for 2 cycles before the start of RT and for 4 cycles after the end of radiation treatment in CT + RT arm. Among the 58 evaluable patients objective response rate was as follows: in RT arm, CR in 40.7{\%} of patients, PR in 40.7{\%}, and SD in 18.6{\%}; in CT + RT arm, CR in 42{\%} of patients, PR in 35.5{\%}, and SD in 22.5{\%}. The median duration of response was 12 months (range: 3-38 + months). At a median follow-up of 36 months survival (S) and progression-free survival (PFS) were 83{\%} and 72.4{\%} in RT arm, 72{\%} and 59.3{\%} in CT + RT arm, respectively. No significant difference was observed between the 2 treatment arms, neither in terms of objective response nor in terms of S and PFS. Both treatments were generally well tolerated. In our experience the addition of chemotherapy to standard radiotherapy does not enhance morbidity and does not interfere with the correct delivery of the planned treatment. However, results of this combined modality regimen remain unsatisfactory, since no improvement in pelvic control and survival of patients with advanced cervical carcinoma was observed.",
author = "S. Chiara and M. Bruzzone and L. Merlini and P. Bruzzi and R. Rosso and P. Franzone and M. Orsatti and V. Vitale and G. Foglia and F. Odicino and N. Ragni and S. Rugiati and P. Conte",
year = "1994",
language = "English",
volume = "17",
pages = "294--297",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma

AU - Chiara, S.

AU - Bruzzone, M.

AU - Merlini, L.

AU - Bruzzi, P.

AU - Rosso, R.

AU - Franzone, P.

AU - Orsatti, M.

AU - Vitale, V.

AU - Foglia, G.

AU - Odicino, F.

AU - Ragni, N.

AU - Rugiati, S.

AU - Conte, P.

PY - 1994

Y1 - 1994

N2 - Between January 1989 and December 1991, 64 patients with advanced cervical carcinoma FIGO stage IIb-III were randomized to receive radiotherapy (RT) alone or the sequential combination of chemotherapy (CT) and RT. RT consisted of external RT (40 Gy fractionated over 4 weeks) + brachytherapy (40 Gy to point A) + an additional boost to the parameters (15-20 Gy) in arm RT; CT consisted of cisplatin 60 mg/m2 i.v. day 1 q 15 days administered for 2 cycles before the start of RT and for 4 cycles after the end of radiation treatment in CT + RT arm. Among the 58 evaluable patients objective response rate was as follows: in RT arm, CR in 40.7% of patients, PR in 40.7%, and SD in 18.6%; in CT + RT arm, CR in 42% of patients, PR in 35.5%, and SD in 22.5%. The median duration of response was 12 months (range: 3-38 + months). At a median follow-up of 36 months survival (S) and progression-free survival (PFS) were 83% and 72.4% in RT arm, 72% and 59.3% in CT + RT arm, respectively. No significant difference was observed between the 2 treatment arms, neither in terms of objective response nor in terms of S and PFS. Both treatments were generally well tolerated. In our experience the addition of chemotherapy to standard radiotherapy does not enhance morbidity and does not interfere with the correct delivery of the planned treatment. However, results of this combined modality regimen remain unsatisfactory, since no improvement in pelvic control and survival of patients with advanced cervical carcinoma was observed.

AB - Between January 1989 and December 1991, 64 patients with advanced cervical carcinoma FIGO stage IIb-III were randomized to receive radiotherapy (RT) alone or the sequential combination of chemotherapy (CT) and RT. RT consisted of external RT (40 Gy fractionated over 4 weeks) + brachytherapy (40 Gy to point A) + an additional boost to the parameters (15-20 Gy) in arm RT; CT consisted of cisplatin 60 mg/m2 i.v. day 1 q 15 days administered for 2 cycles before the start of RT and for 4 cycles after the end of radiation treatment in CT + RT arm. Among the 58 evaluable patients objective response rate was as follows: in RT arm, CR in 40.7% of patients, PR in 40.7%, and SD in 18.6%; in CT + RT arm, CR in 42% of patients, PR in 35.5%, and SD in 22.5%. The median duration of response was 12 months (range: 3-38 + months). At a median follow-up of 36 months survival (S) and progression-free survival (PFS) were 83% and 72.4% in RT arm, 72% and 59.3% in CT + RT arm, respectively. No significant difference was observed between the 2 treatment arms, neither in terms of objective response nor in terms of S and PFS. Both treatments were generally well tolerated. In our experience the addition of chemotherapy to standard radiotherapy does not enhance morbidity and does not interfere with the correct delivery of the planned treatment. However, results of this combined modality regimen remain unsatisfactory, since no improvement in pelvic control and survival of patients with advanced cervical carcinoma was observed.

UR - http://www.scopus.com/inward/record.url?scp=0027964210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027964210&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 294

EP - 297

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -